NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.39 +0.21 (+6.60 %)
(As of 06/24/2018 06:45 AM ET)
Previous Close$3.39
Today's Range$3.12 - $3.39
52-Week Range$2.09 - $4.51
Volume2.29 million shs
Average Volume891,616 shs
Market Capitalization$326.26 million
P/E Ratio-16.14
Dividend YieldN/A
Beta1.57
Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio28.91
Quick Ratio28.91

Price-To-Earnings

Trailing P/E Ratio-16.14
Forward P/E Ratio-9.97
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book4.29

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-18,410,000.00
Net MarginsN/A
Return on Equity-34.74%
Return on Assets-32.93%

Miscellaneous

Employees21
Outstanding Shares102,600,000

The Truth About Cryptocurrencies

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Catalyst Pharmaceuticals.

What price target have analysts set for CPRX?

4 equities research analysts have issued 12-month target prices for Catalyst Pharmaceuticals' shares. Their predictions range from $5.00 to $8.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $6.25 in the next twelve months. View Analyst Ratings for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "AT-014 Conditional Approval: Further Attestation to Strategy AT-014 receives a conditional licensure from the USDA. On December 20, Aratana announced that the USDA Center for Veterinary Biologics has granted AT-014 conditional marketing approval for the treatment of canine osteosarcoma. AT-014 is a canine cancer vaccine derived from listeria that targets HER2/neu, a causative mutation of canine osteosarcoma. In pilot studies, AT-014 treatment of dogs with osteosarcoma (n=18) increased their median overall survival (mOS) to 956 days compared to 423 days for historical controls (p<0.05). Therefore, following the USDA approval we believe that AT-014 can quickly become a preferred therapeutic option for this difficult-to-treat indication. With four product approvals in two years, we believe the success of AT-014 is a further attestation of management's strategy of bringing advanced human therapies to the veterinarian market."" (12/21/2017)
  • 2. According to Zacks Investment Research, "Catalyst Pharma posted narrower than expected loss in the third quarter of 2017. Earlier in 2016, the company received a refusal to file letter from the FDA in connection with the NDA for Firdapse. The company suffered a setback when it received a refusal to file letter for Firdapse from the FDA.  Nevertheless, the company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in early December 2017 and resubmit a new drug application (NDA) before the end of 2017. Catalyst has a limited number of candidates in its pipeline and is highly dependent on Firdapse’s approval for growth.  Meanwhile, the company is also developing Firdapse for additional indications. The company’s share price movement shows that the stock has outperformed the industry year to date. " (11/14/2017)

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 71)
  • Ms. Alicia Grande CPA, CMA, Chief Financial Officer, Chief Accounting Officer, VP and Treasurer (Age 47)
  • Dr. Steven R. Miller Ph.D., Chief Operating Officer and Chief Scientific Officer (Age 56)
  • Dr. Gary Ingenito M.D., Ph.D., Chief Medical Officer and Head of Regulatory Affairs (Age 62)
  • Mr. Brian Elsbernd, Sr. VP of Legal and Compliance (Age 54)

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

News articles about CPRX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 44.16 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.58%), venBio Select Advisor LLC (4.57%), Millennium Management LLC (1.35%), JPMorgan Chase & Co. (1.12%), Northern Trust Corp (0.98%) and Knott David M (0.48%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Which major investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., A.R.T. Advisors LLC and Citadel Advisors LLC. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Which major investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, BlackRock Inc., Gables Capital Management Inc., JBF Capital Inc., Northern Trust Corp, Sofinnova Ventures Inc, Knott David M and GSA Capital Partners LLP. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $3.39.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $326.26 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]


MarketBeat Community Rating for Catalyst Pharmaceuticals (CPRX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.